NEW YORK (360Dx) – Genomica and HuaSin on Monday announced that they have entered an agreement by which HuaSin obtained exclusive rights to develop and produce a fully automated HPV genotyping assay platform that uses Genomica's technology.
Financial and other terms of the deal were not disclosed.
Guangzhou, China-based HuaSin has commenced a registration process with the China Food and Drug Administration, and subject to regulatory approval anticipates launching the platform in China in 2021.
HuaSin said it expects the genotyping technology will help detect HPV in women before cancer develops and spreads, and it hopes that the technology will also support "long-needed and evolving" vaccination programs.
The potential to market the fully automated HPV Clinical Arrays Technology (Clart) test into China supports Genomica's mission to enable as many women in the world as possible to test their HPV status, Rosario Cospedal, CEO of the Madrid, Spain-based firm, said in a statement.
Of more than 500,000 new cases of cervical cancer each year, about 130,000 occur in China, the firms said.